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Abstract
Background: Therapy with mycophenolate mofetil (MMF) has become a valuable therapeutic option in children
with autoimmune disease. MMF prescription in children with autoimmune diseases differs from that in transplant
recipients in terms of different dosing regimen, and concomitant administration of other immunosuppressive
medications. Recently, another formulation of the same active compound, mycophenolic acid (MPA), has become
available as enteric-coated Mycophenolate Sodium (EC-MPS). Dosing and pharmacokinetics of EC-MPS in pediatric
autoimmune disease have never been studied.
Methods: We therefore performed a pilot study on 6 patients, who were treated with EC-MPS. All patients
underwent 1-2 full 10-point pharmacokinetic (PK) profiles over a 12-hour dosing interval. We compared the results
with that of 22 similar patients on MMF therapy.
Results: Median EC-MPS dose was 724 mg/m
2 (range 179-933 mg/m
2). The MPA Area-Under-The-(Time-
Concentration)-Curves (AUCs) on MMF and EC-MPS were comparable (54.4 mg × h/L on MMF and 44.0 mg × h/L
on EC-MPS, n.s., Mann Whitney). After correcting for bioequivalence, the dose-normalized AUCs were also similar
on both the formulations. However, PK profiles on EC-MPS were quite random, and time to maximum
concentration varied from 30 minutes to 720 minutes. The concentration at six-hour correlated best with the AUC.
This was different from a homogenous PK-profile on MPA.
Conclusions: EC-MPS has a different PK profile from MMF. The data suggest that patients on EC-MPS must
undergo a complete PK profile to assess adequate exposure. The 6-hour concentration provides an estimate of the
exposure and should be targeted between 3-4 mg/L.
Background
Mycophenolate mofetil (MMF) is an immunosuppressive
drug that reversibly inhibits the inosin monophosphate
dehydrogenase (IMPDH), thereby providing selective
inhibition of the proliferation of B and T-cells as they
require de-novo synthesis of purines [1]. MMF has
become a valuable treatment option for adults and chil-
dren with autoimmune diseases. A recent randomized
controlled clinical trial suggests equal efficacy when
compared to cyclophosphamide for the initial treatment
of lupus nephritis [2]. There are few publications on the
dosing of MMF. Based on pharmacokinetic studies in
children with autoimmune disease, an initial dosing of
MMF at 900 mg/m
2 in two divided doses is recom-
mended [3]. This dose is lower than that recommended
for pediatric renal transplant recipients, where the start-
ing dose should be between 1200 and 2400 mg/m
2,
depending on the concomitant calcineurin inhibitor.
The reasons for different dosing of MMF in pediatric
rheumatology patients as compared to pediatric renal
transplant patients is explained by the lack of a conco-
mitant calcineurin inhibitor. There are drug-drug inter-
actions between both calcineurin inhibitors and MMF
that explain the variable dosing requirements [4].
The AUCs obtained with the pediatric MMF dose of
900 mg/m
2 in pediatric lupus patients compare favor-
ably or slightly higher than those in adults on a dose of
1 g PO twice daily [5]. Therapeutic drug monitoring
(TDM) of MMF therapy is recommended in patients
with autoimmune disease and typically done by trough
level monitoring because of high inter-individual varia-
bility and unpredictable MPA exposure with a fixed
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nological disease activity parameters [6].
Recently, a novel formulation of the active compound,
mycophenolic acid (MPA), was introduced as enteric-
coated mycophenolate sodium (EC-MPS). It was hoped
that this compound reduced the frequent gastrointest-
inal side effects of MMF [7]. In the province of Ontario,
the government no longer reimburses MMF for patients
with autoimmune disease, thereby forcing physicians to
prescribe EC-MPS instead. While the literature suggests
that the pharmacokinetics are radically different in
transplant recipients (reviewed in 5), studies on the
pharmacokinetics of EC-MPS in children with autoim-
mune disease remain elusive. We compared the results
of 5 patients with EC-MPS with historical PK profiles
from 22 patients who received MMF therapy.
Methods
Patients
The previous study [3] that established the dosing of
MMF in pediatric rheumatological patients was
approved by the hospital Research Ethics Committee. As
only six patients were on EC-MPS, and as pharmacoki-
netic monitoring of MMF and EC-MPS therapy is clini-
cal routine in our unit, we did not seek ethics approval
for the analysis of the PK profiles from these six
patients. Of these six patients, three had Systemic Lupus
Erythematosus (SLE), one had sarcoidosis and two had
an autoimmune glomerulonephritis.
The control group with MMF therapy has been
described earlier [3]. In addition to the 15 patients that
were published, 7 additional patients with SLE were
included. All underwent standard immunosuppressive
treatment prior to MMF initiation. MMF (Cellcept®) was
obtained from Roche Laboratories, Nutley, NJ, USA.
Only 250 and 500 mg capsules were used. The patients
on EC-MPS were treated with Myfortic® obtained from
Novartis Canada, Mississauga, ON, Canada, and 180
and 360 mg capsules were used.
Methods
Standard laboratory test results were retrieved from the
patient’s files. All patients (on MMF or EC-MPS) under-
went therapeutic MPA monitoring using trough levels
with a commercially available automated EMIT assay
[8]. After establishment of stable trough concentrations
between 1 and 5 mg/L, all patients had at least one full
pharmacokinetic (PK) profile. PK profiles were obtained
after inserting an intravenous cannula and obtaining a
baseline trough level (C0) in a fasting state usually early
morning. The patients then took their usual dose of
MMF or EC-MPS and immediately thereafter ate a stan-
dard meal. They had free access to non-dairy product
drinks during the day and regular meals. EDTA whole
blood samples (2 mL) were then taken for duplicate
measurements of MPA concentration at 0.5, 1, 1.5, 2, 3,
4, 6, 8 and 12 hours, respectively for a 10 point 12 hour
PK profile. The area under the curve was calculated
according to the trapezoid rule.
Statistics
All contiguous data were tested for normal distribution
using the Kolmogorov Smirnov test. In case of normally
distributed data, results were presented as mean ± stan-
dard deviation (SD), whereas non-normally distributed
data were expressed as median and 25
th and 75
th per-
centile. Standard correlation analysis was performed
using appropriate parametric or non-parametric
approaches. Comparisons between groups were per-
formed using t-test for normally distributed data and
Mann-Whitney test otherwise. A p value of less than
0.05 was considered significant. All statistical analysis
was performed using GraphPad Software for Science
Version 4.01, San Diego, CA.
Results
All variables under study were investigated for normality
using the Kolmogorov Smirnov normality test and most
variables were found to be not normally distributed. For
consistency, all statistical measures of parameters were,
therefore, reported as median, 25
th and 75
th percentile.
The analysis of the PK profiles of the 22 patients with
pediatric autoimmune disease is given in figure 1. Fol-
lowing oral administration, the drug is rapidly absorbed
(median tmax 60 minutes, a second peak at 6 hours,
figure 1).
By contrast, tmax was later on EC-MPS with a median
of 180.0 minutes (25
th percentile 60 minutes, 75
th per-
centile 240 minutes, range 30 to 720 minutes). Median
Cmax was 20.1 mg/L (25
th percentile 10.3, 75
th percentile
4 5 . 1 ) .T h em e d i a np r e - d o s et r o u g hl e v e lC 0w a s2 . 7 6
mg/L (25
th percentile 2.29, 75
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2 body surface area had a median of
724.2 mg/m
2 (25
th percentile 660.2, 75
th percentile
Figure 1 The relationship between time after intake of MMF
[hours] and the median MPA concentration as well as the 25th
and 75th percentile.
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Page 2 of 5859.2). MPA AUC on EC-MPS had a median of 44.0 mg
× h/L (25
th percentile 42.0 mg × h/L, 75
th percentile 196
mg × h/L), not significantly different from the median
AUC from the 22 patients on MMF who had a median
AUC of 57.9 mg × h/L (unpaired t-test). The bioequiva-
lent dose for 250 mg of MMF is 180 mg of EC-MPS.
The median dose of 724.2 mg/m
2 would be equivalent
to 1005.8 mg/m
2 of MMF which compared to a median
of 893 mg/m
2 that the 22 patients on EC-MPS were
given (not significant). The dose normalized MPA AUC
had a median of 0.11 mg × m
2 ×h / L×m g( 2 5
th per-
centile 0.05, 75
th percentile 0.25 mg × m
2 ×h / L×m g ) .
The dose normalized MPA-AUC in the 22 patients on
EC-MPS was 0.057 m
2 × h/L. After conversion of the of
the EC-MPS dose to a bioequivalent dose of MMF, the
dose normalized AUC no longer differed from that of
the patients on MMF (bioequivalent EC-MPS AUC was
0.14 mg × m
2 ×h / L×m g ,p>0 . 0 5 ,M a n nW h i t n e y
test). This suggests that in pediatric patients with auto-
immune disease the same conversion of the dose with
250 mg of MMF being equivalent to 180 mg of EC-MPS
is applicable.
Patients on EC-MPS showed random PK profiles
(figure 2). For the convenience of the reader, we super-
imposed the actual PK profiles over the percentiles of
the MMF profiles.
We then studied whether the trough level could be used
to assess the MPA exposure in patients on EC-MPS.
Spearman correlation coefficients between AUC and the
different Cn trough level points revealed no correlation
between the trough level. The best correlation was for the
6-hour concentration (Spearman r = 0.919). The median
C6 level was 3.21 mg/L, the 25
th percentile for the C6 was
1.20 mg/L and the 75
th percentile was 13.5 mg/L. The
results of the correlation studies are provided in table 1.
AUC could not be estimated on the basis of the C0,C 1,
C2,o rC 4 concentrations, which are time points commonly
used for limited sampling strategies. Based on the preli-
minary data from these 6 patients, the 6-hour concentra-
tion should be targeted between 3-4 mg/L.
Figure 2 Six individual pharmacokinetic PK profiles of 6 pediatric patients with autoimmune disease on EC-MPS, superimposed on
figure 1.
Table 1 Correlation between exposure (12-hour AUC determined by full 10-point PK profile, calculated using the
trapezoid rule) and individual time concentration points.
Parameter C0 C0.5 C1 C1.5 C2 C3 C4 C6 C8 C12
Number of
XY Pairs
7777777777
Spearman r 0.3929 0.7500 0.2162 0.2162 0.8571 0.7857 0.8571 0.9190 0.6786 0.6786
P value (two-
tailed)
0.3956 0.0663 0.6615 0.6615 0.0238 0.0480 0.0238 0.0067 0.1095 0.1095
P value
summary
n s n s n s n s **** * n s n s
Exact or
approximate
P value?
Exact Exact Exact Exact Exact Exact Exact Exact Exact Exact
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The objective of the study was the characterization of
the pharmacokinetics of EC-MPS in pediatric patients
with autoimmune disease without a concomitant calci-
neurin inhibitor. As outlined in the introduction, this
was necessary as special dosing is required and data
from transplant patients cannot simply be applied to
these patients. Secondary objectives were to determine
whether the recommendations for bioequivalence of
dosing can be applied to pediatric patients with autoim-
mune disease and whether trough level monitoring is
feasible to study exposure in these children.
The study demonstrates that bioequivalent dosing of
EC-MPS can indeed be implemented using the same
conversion (180 mg of EC-MPS for 250 mg of MMF).
AUC’s achieved with a median dose of 712 mg/m
2
resulted in comparable MPA exposure. However, there
was substantial inter-individual variability. Furthermore,
tmax was random and only the C6 concentration corre-
lated significantly with the exposure.
A bioequivalent dose of 180 mg of EC-MPS being
equivalent to 250 mg of MMF has been reported for
transplant patients[9]. This has not been shown for
pediatric rheumatology patients. This paper provides the
first evidence that the same conversion can be applied
with comparable AUCs. When correcting for the bioe-
quivalence, the dose-normalized MPA AUCs are also
similar. As such, the clinician may switch between both
formulations should the gastrointestinal (GI) side effects
prevent ongoing use of MMF. However, the jury
remains out as to whether conversion to EC-MPS
improves the GI side effects [10]. We are unaware of
any study in SLE patients that compares GI side effects
of both formulations. The GI tolerability of MMF ther-
apy appears less of a problem than in transplant
patients, possibly because of the use of concomitant cal-
cineurin inhibitors [11].
Importantly, there was substantial inter-patient varia-
bility. There was a wide range of the dose-normalized
AUC (maximum 5.6 higher than minimum), confirming
data on liver transplant patients that suggest wide inter-
patient variability [12]. These data stress the need for
TDM in pediatric rheumatology patients as has also
been shown for adult patients [6]. As with MMF, we
recommend that at least one full PK profile be obtained
on stable dosing in these patients [3]. Unfortunately,
trough level monitoring, which forms the mostly widely
used TDM strategy, is not feasible in these patients.
There is absolutely no correlation at all between AUC
and C0 or C12.I ti sw e l le s t a b l i s h e dt h a tt r o u g hl e v e l
monitoring of MPA is insufficient in transplant recipi-
ents [13]. Limited sampling strategies are used instead,
most commonly involving C0,C 1,C 2 and C4 [14]. Based
on the preliminary results in this study, these strategies
will fail. Only the C6 concentration correlates signifi-
cantly with the trough level. Our study provides insuffi-
cient numbers to establish a limited sampling model
based on the C6 concentration. The authors encourage
multi-center studies on pediatric rheumatology patients
on EC-MPS to establish such strategies. Until these
become available, a full PK profile should be entertained
to determine that patients have adequate exposure.
The question about what exactly comprises adequate
exposure remains to be determined. Recent evidence
from transplant studies suggests that an AUC greater
than 30 mg × h/L is required to prevent rejection [15].
However, no upper therapeutic window could be estab-
lished. Generally, SLE patients are aimed at a higher
AUC [6], and the therapeutic window has not yet been
formally confirmed in randomized controlled clinical
trials. It appears that the EC-MPS dose of 712 mg/m
2
may provide adequate exposure with a target AUC of 60
mg × h/L. None of the patients relapsed on the respec-
tive doses with their measured AUCs, but the follow-up
is short (367 days, range 106-612 days, data not shown
in results) and the numbers are insufficient to draw any
conclusions.
Our study is limited by the small number of patients
studied. Nonetheless, the observation of the random
tmax and the very substantial inter-patient variability
clearly warrants the need for TDM in these patients.
The limited sampling strategies typically employed for
MMF therapy are inadequate, thus further studies are
needed to assess the feasibility of the 6-hour concentra-
tion. The authors stress the need for TDM in these
patients using full PK profiles.
Conclusion
A full pharmacokinetic profile is required to assess the
MPA exposure when treating patients with EC-MPS.
The 6-hour concentration can provide a rough estimate
of this exposure. Based on the preliminary data from
only 6 patients, the 6-hour concentration should be tar-
geted between 3-4 mg/L.
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